Parasitological, Histopathological and Regulatory Micro RNA Assessment in Chronic Murine Toxoplasmosis Treated with Bee Venom | ||
| Egyptian Journal of Veterinary Sciences | ||
| Articles in Press, Corrected Proof, Available Online from 17 March 2025 PDF (1.03 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ejvs.2025.343507.2552 | ||
| Authors | ||
| Mai A. Moubarak* 1; Rabab S. Zalat2; Mona S. El-Sherbini3; Marwa Hassan4; Ahmed H.A. Eassa5; Mousa A.M. Ismail5 | ||
| 116th Samir Morsy street, Nasr City, Cairo,Egypt | ||
| 2Theodor Bilharz research Institute, Giza,Egypt | ||
| 3Faculty of Medicine, Cairo University | ||
| 4Theodor Bilharz Research Institute, Giza,Egypt | ||
| 5Department of Medical Parasitology, Faculty of Medicine, Cairo University, Egypt. | ||
| Abstract | ||
| This research aimed to compare the potential anti-toxoplasma impact of Bee venom (B.v.) against the commercial drug spiramycin (SPI) on chronic toxoplasmosis parasitologically. A histopathological evaluation of the me49 infection was performed on the brain, liver, and lungs. Host regulatory microRNAs miR-712-3p and miR-146b-5p were measured before and after the tested drugs were administered in the sera of Swiss albino mice. Group A served as the control group, subdivided into 4 subgroups, while Group B was further separated into four me49 infected subgroups. When compared to the positive control, the combination of B.v. and SPI had the best outcomes, with a statistically significant 94.1% reduction in brain cyst count. Me49 infection resulted in a significant rise in the level of miR-712-3p expression in rats’ serum. Furthermore, after infection, there was a 50-fold rise in miR-146b-5p in host sera. Following the tested medications' treatment of the diseased mice, these levels dropped. | ||
| Keywords | ||
| Toxoplasma; Me49 strain; Bee venom; Spiramycin; miR-712-3p; miR-146b-5p; Histopathology; Mice | ||
|
Statistics Article View: 158 PDF Download: 70 |
||
